DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Direct immunofluorescence and specialist referral

Essential points for quick revision.

!
Unstable blistering or mucosal disease

Skin pain, systemic toxicity, rapid detachment, widespread denudation, inability to drink, ocular symptoms, airway concern, genital or urinary involvement, pregnancy-associated blistering, infant disease or suspected severe infection makes specimen collection secondary to stabilisation.

Action: Arrange same-day hospital and dermatology assessment, stop plausible culprit medicines where appropriate and protect fluids, temperature, analgesia, eyes and mucosa; obtain correctly targeted samples early if safe, but never delay resuscitation or urgent treatment solely to preserve immunofluorescence yield.

Synopsis

Choose, consent, collect and transport skin for direct immunofluorescence, interpret major deposit patterns in clinical context, and route blistering, vasculitic and connective-tissue presentations to the right urgency of specialist care.

  • Direct immunofluorescence detects immunoglobulin, complement or fibrin deposited in the patient's skin; it is different from routine H&E histology and indirect immunofluorescence performed on serum.
  • Autoimmune blistering investigation usually needs two separately selected punch biopsies: a fresh blister edge or lesional sample in formalin for H&E and intact perilesional skin in the laboratory's fluorescence transport system for DIF.
  • For dermatitis herpetiformis, choose normal-appearing skin immediately beside a fresh lesion; eroded, excoriated or directly involved tissue can lose the diagnostic granular IgA signal.

Key red flags

Rapid spread, Nikolsky-positive or painful skin, fever, hypotension, extensive erosions, eye pain or visual change, dysphagia, reduced intake or urine, breathing symptoms, genital involvement, immunosuppression or a vulnerable age group requires urgent specialist triage before routine biopsy booking.

Severe epithelial loss

Pain, flat duskiness, detachment, fever or multi-site mucositis points to an emergency drug reaction or other severe disease in which referral precedes an elective test pathway.

Investigation priorities

01
Clinical map before samplingFirst step

Define the leading disease, choose lesion age and preserve a record for clinicopathological correlation.

Management branches

First decisionDefine urgency before diagnostic elegance

A blistering, erosive, purpuric or interface eruption may need immunofluorescence.

  1. Assess observations, skin pain and extent, hydration, infection, mouth, eyes, genital and airway involvement and systemic renal, gastrointestinal, neurological or respiratory features.
  2. Arrange emergency admission and dermatology review for instability or threatened epithelium and begin time-critical supportive or disease-directed care without waiting for an ideal specimen.
Consent and preparationPlan two answers and two wounds

H&E and DIF are both needed to investigate a stable patient.

Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom